Global Peripheral Blood Mononuclear Cells Market is Expected to Register 10.09% Growth Driven by Rising Demand for Cell-Based Therapies and Immunology Research

Global peripheral blood mononuclear cells (PBMCs) market is experiencing steady growth, driven by increasing research in immunology, rising investments in cell-based therapies, and the growing need for high-quality biospecimens for drug discovery and clinical trials.

According to the Markets and Data Research report, “Global Peripheral Blood Mononuclear Cells Market Assessment, Opportunities and Forecast, 2018-2032F”, The market for peripheral blood mononuclear cells is projected to grow at a CAGR of 10.09% from 2025 to 2032. The market size is expected to increase from USD 335.91 million in 2024 to USD 729.21 million by 2032. The increasing adoption of PBMCs in next-generation vaccines, regenerative medicine, and precision therapies, along with favorable regulatory initiatives and advancements in biobanking infrastructure, are major contributors to market expansion.

The surging demand for cryopreserved peripheral blood mononuclear cells among research organizations and contract research organizations (CROs) is propelling the market forward. These cells offer high reliability and scalability for multi-site clinical studies and long-term storage. Moreover, the rise of immunology research, especially in autoimmune diseases, cancer immunotherapy, and infectious diseases is accelerating peripheral blood mononuclear cells usage. Leading players such as Lonza Group AG, Charles River Laboratories, and Bio-Rad Laboratories continue to invest in advanced biobanking and isolation technologies to enhance sample quality and accessibility.

The "Global Peripheral Blood Mononuclear Cells Market" report is 267 pages long and includes an in-depth TOC, over 158 market data figures, the latest market developments, key drivers and opportunities, and a thorough study of major company profiles. Moreover, the report offers strategic recommendations, pricing analysis, market share analysis, and value chain analysis in detail.

Click Here To Get Full Analysis Report: https://www.marketsandata.com/industry-reports/peripheral-blood-mononuclear-cells-market

Key Takeaways:

• The demand for PBMCs is fueled by increasing cell-based therapy research, growing use in immunology studies, and rising adoption in vaccine development.
• Cryopreserved PBMCs remain the dominant segment due to their consistency, scalability, and ease of transport for global clinical trials.
• Immunology research continues to lead applications for PBMCs, supported by increased focus on immune profiling and immunotherapy development.
• North America remains the largest market for PBMCs, while Asia-Pacific is witnessing rapid growth driven by rising healthcare investments and expanding biobanking infrastructure.

Global peripheral blood mononuclear cells market is segmented in the following categories:

By Product: Cryopreserved or Frozen PBMC, Culture or Fresh PBMC, PBMC Isolation & Viability Kits

By Application: Immunology, Haematology, Vaccine Development, Toxicology, Infectious Disease, Others

By Techniques: Density Gradient Centrifugation, Leukapheresis, Others

By Source: Human, Animal

By Region: North America, Europe, South America, Asia-Pacific, Middle East and Africa

Based on product, cryopreserved PBMCs lead the market due to their proven ability to maintain cellular integrity and viability over extended periods. This durability supports reproducibility across multi-center clinical studies, which is crucial for generating consistent and reliable data. Their standardized handling protocols, easy global transportability, and compatibility with automated biobanking systems make them ideal for pharmaceutical companies, CROs, and academic researchers managing large-scale immunological studies.

Among techniques, density gradient centrifugation continues as the gold standard because of its simplicity, affordability, and consistent performance in isolating pure PBMCs. It is widely adopted across labs and remains well-suited for routine immune studies. On the other hand, leukapheresis is gaining prominence in cutting-edge therapies like CAR-T and stem cell treatments. Its ability to extract larger quantities of viable mononuclear cells enables scalable cell production for therapeutic applications, despite requiring more specialized infrastructure.

By source, human PBMCs dominate due to their direct applicability in understanding and treating human diseases. Their compatibility with regulatory frameworks and translational research makes them the top choice for developing personalized therapies and evaluating immune responses. Meanwhile, animal-derived PBMCs support foundational research, particularly in comparative studies and preclinical drug testing, where they offer valuable insights into immune biology across species.

North America holds the largest market share, driven by its sophisticated clinical trial networks, advanced biobanking capabilities, and strong financial backing for biomedical research. The region’s mature healthcare ecosystem enables widespread PBMC adoption across academic and commercial sectors. Asia-Pacific, meanwhile, is rapidly emerging with growing investments in healthcare infrastructure, rising participation in global research collaborations, and expanding biospecimen management systems. The region’s proactive policies and research growth make it a key future market for PBMC expansion.

Download Free Sample Report

Major Companies Operating in Global Peripheral Blood Mononuclear Cells Market Include:

• Lonza Group AG
• Charles River Laboratories International, Inc.
• Bio-Rad Laboratories Inc.
• Corning Incorporated
• Thermo Fisher Scientific Inc.
• BioIVT LLC
• Ixcells Biotechnologies USA, Inc.
• Precision Medicine Group, LLC
• Biopredic International
• CGT Global LLC

Strategic collaborations, acquisitions, and capacity expansions are shaping the competitive landscape. Lonza, for example, has recently scaled its global biobanking services, while Charles River has bolstered its immunology portfolio through strategic partnerships.

In June 2025, iXCells Biotechnologies announced the launch of its modular iPSCore platform. This platform is designed to generate highly characterized iPSC-derived human cell models. The platform processes over 1,000 samples per year with a high success rate and aims to significantly multiply the output of patient-derived iPSC-derived cells by 2026. This innovation directly leverages PBMCs as a source material for creating advanced iPSC models.

“Global Peripheral Blood Mononuclear Cells Market Assessment, 2018-2032F”, evaluates the future growth potential of global peripheral blood mononuclear cells market and provides statistics and information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision-makers make strategic investment decisions for their organizations. Moreover, the report identifies and examines the emerging trends along with key drivers, challenges, and opportunities in the global peripheral blood mononuclear cells market.

Contact

Mr. Vivek Gupta

5741 Cleveland street,

Suite 120, VA beach, VA, USA 23462

Tel: +1 (757) 343–3258

Email: info@marketsandata.com

Website: https://www.marketsandata.com